{"name":"Supergene, LLC","slug":"supergene-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Non-immunogenic recombinant staphylokinase","genericName":"Non-immunogenic recombinant staphylokinase","slug":"non-immunogenic-recombinant-staphylokinase","indication":"Acute myocardial infarction","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"non-immunogenic staphylokinase","genericName":"non-immunogenic staphylokinase","slug":"non-immunogenic-staphylokinase","indication":"Treatment of acute ischemic stroke","status":"phase_3"}]}],"pipeline":[{"name":"Non-immunogenic recombinant staphylokinase","genericName":"Non-immunogenic recombinant staphylokinase","slug":"non-immunogenic-recombinant-staphylokinase","phase":"phase_3","mechanism":"Non-immunogenic recombinant staphylokinase is a fibrinolytic enzyme that directly activates plasminogen to plasmin, dissolving blood clots without triggering immune responses.","indications":["Acute myocardial infarction","Acute ischemic stroke","Pulmonary embolism","Deep vein thrombosis"],"catalyst":""},{"name":"non-immunogenic staphylokinase","genericName":"non-immunogenic staphylokinase","slug":"non-immunogenic-staphylokinase","phase":"phase_3","mechanism":"Non-immunogenic staphylokinase is a genetically engineered enzyme that catalyzes the conversion of plasminogen to plasmin, thereby dissolving blood clots.","indications":["Treatment of acute ischemic stroke","Treatment of pulmonary embolism"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}